Global Tranexamic Acid Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Tranexamic Acid Market Size

• The global tranexamic acid market size was valued at USD 86.59 billion in 2024 and is expected to reach USD 135.95 billion by 2032, at a CAGR of 5.80% during the forecast period
• The market growth is largely fueled by the increasing use of tranexamic acid in medical applications such as trauma care, surgical procedures, and heavy menstrual bleeding, due to its effectiveness in reducing blood loss and improving patient outcomes. The expanding use in both hospital and outpatient settings highlights its growing clinical relevance
• Furthermore, rising consumer demand for skin-brightening and anti-pigmentation treatments has led to the incorporation of tranexamic acid in dermatological and cosmetic products. These converging factors are accelerating the uptake of Tranexamic Acid solutions across both pharmaceutical and personal care sectors, thereby significantly boosting the industry's growth

Tranexamic Acid Market Analysis

• Tranexamic Acid, an antifibrinolytic agent used to prevent and treat excessive bleeding, is increasingly recognized in both clinical and cosmetic applications due to its effectiveness, affordability, and safety profile
• The escalating demand for tranexamic acid is primarily fueled by the rise in surgical procedures, trauma cases, heavy menstrual bleeding, and its expanding role in dermatology for treating melasma and hyperpigmentation
• North America dominated the Tranexamic Acid market with the largest revenue share of 38.7% in 2024, driven by high adoption of advanced healthcare practices, increased surgical volume, and strong pharmaceutical distribution channels. The U.S. experienced substantial growth in prescription and OTC Tranexamic Acid formulations, bolstered by regulatory support and awareness campaigns for menstrual health and bleeding disorders
• Asia-Pacific is expected to be the fastest-growing region in the tranexamic acid market during the forecast period, with a projected CAGR of 7.8%, due to rising healthcare infrastructure, growing awareness of dermatological solutions, and increasing cosmetic usage in countries like Japan, South Korea, and India
• Injections segment dominated the tranexamic acid market with a market share of 45.2% in 2024, driven by its widespread use in hospitals for trauma, surgery, and emergency bleeding conditions, coupled with rapid onset of action and established clinical efficacy

Report Scope and Tranexamic Acid Market Segmentation    

Tranexamic Acid Market Trends

“Increasing Medical and Cosmetic Demand Driving Market Expansion”

• A significant and accelerating trend in the global Tranexamic Acid market is the growing utilization of the compound in both medical and cosmetic applications. Tranexamic acid has established its role as an essential antifibrinolytic agent in surgeries, trauma cases, postpartum hemorrhage, and menorrhagia, leading to consistent demand in hospitals and surgical centers
  • For instance, in emergency trauma and obstetric care, global health organizations including WHO have recommended tranexamic acid to reduce mortality from bleeding, further encouraging its inclusion in national essential medicine lists
• In addition to its clinical uses, tranexamic acid has become increasingly popular in dermatology and cosmetics, particularly in skin-brightening formulations and products designed to reduce hyperpigmentation and melasma. Dermatologists and skincare brands are capitalizing on its anti-inflammatory and pigment-lightening properties
• The dual use of tranexamic acid in both therapeutic and aesthetic segments presents a unique advantage, allowing pharmaceutical and cosmetic companies to target diverse consumer needs
• Furthermore, the availability of multiple formulations such as tablets, injections, and topical serums ensures wide adoption across different healthcare settings and consumer segments. This versatility, combined with ongoing R&D and product innovations, is contributing to the robust growth trajectory of the global Tranexamic Acid market

Tranexamic Acid Market Dynamics

Driver

“Growing Demand Due to Rising Incidence of Bleeding Disorders and Expanding Cosmetic Applications”

• The increasing prevalence of hereditary and acquired bleeding disorders, coupled with the growing use of antifibrinolytic agents in trauma care and surgery, is a major driver of demand in the Tranexamic Acid market
  • For instance, in January 2024, the World Federation of Hemophilia reported a notable rise in the global diagnosis rates of bleeding disorders, spurring demand for effective treatments such as tranexamic acid
• In addition, tranexamic acid is witnessing surging popularity in the dermatology and aesthetics space, particularly for treating melasma, post-inflammatory hyperpigmentation, and other skin discoloration concerns—thereby expanding its therapeutic footprint
• The drug’s affordability, efficacy in reducing blood loss during surgical procedures, and minimal side effects compared to other alternatives make it a preferred choice in both developed and emerging healthcare markets
• The growing adoption of tranexamic acid in oral, topical, and injectable forms for both clinical and cosmetic uses is significantly contributing to the market’s expansion, especially in regions with increasing access to elective procedures and skincare treatments

Restraint/Challenge

“Concerns Regarding Adverse Effects and Regulatory Barriers”

• Despite its widespread use, concerns remain about the potential side effects of tranexamic acid, including risks of thrombosis in susceptible patients. These safety concerns limit broader adoption, especially in populations with cardiovascular comorbidities
• In April 2023, the U.S. FDA issued additional labeling guidance for antifibrinolytic agents, emphasizing caution in patients with a history of thromboembolic events, further impacting prescriber confidence
• Moreover, off-label use of tranexamic acid—especially in dermatology—faces regulatory scrutiny in some regions, hindering uniform market growth
• Another key challenge is the lack of awareness among general practitioners and consumers in low- and middle-income countries, where bleeding disorders often go underdiagnosed and untreated
• Addressing these challenges through ongoing clinical research, updated safety guidelines, and targeted education programs for healthcare providers will be essential to unlocking the full potential of the Tranexamic Acid market

Tranexamic Acid Market Scope

The market is segmented on the basis of type, form, application, end users, and distribution channel.

• By Type

On the basis of type, the Tranexamic Acid market is segmented into USP25, BP2000, and others. The USP25 segment dominated the market with the largest revenue share of 46.3% in 2024, driven by its widespread use in pharmaceutical-grade formulations and global regulatory approval.

The BP2000 segment is expected to register the fastest CAGR of 7.2% from 2025 to 2032, owing to its affordability and growing usage in generic formulations across emerging economies.

• By Form

On the basis of form, the tranexamic acid market is segmented into tablets, injections, and oral liquid. Injections segment dominated the market with a market share of 45.2% in 2024, driven by its widespread use in hospitals for trauma, surgery, and emergency bleeding conditions, coupled with rapid onset of action and established clinical efficacy

The tablets segment is expected to witness the fastest CAGR from 2025 to 2032, due to its high patient compliance, convenience, and availability for chronic treatments such as menorrhagia

• By Application

On the basis of application, the tranexamic acid market is segmented into trauma, craniocerebral trauma, menorrhagia, postpartum hemorrhage, surgery, whitening cosmetics, and others. The menorrhagia segment accounted for the largest revenue share of 31.8% in 2024, due to the frequent use of tranexamic acid as a first-line treatment for heavy menstrual bleeding.

The whitening cosmetics segment is expected to register the highest CAGR of 9.7% from 2025 to 2032, driven by rising demand for skin-brightening agents in Asia-Pacific and the Middle East.

• By End Users

On the basis of end users, the tranexamic acid market is segmented into clinics, hospitals, diagnostic centres, and others. The hospitals segment dominated the market with a revenue share of 59.2% in 2024, reflecting the extensive use of tranexamic acid in surgical, trauma, and postpartum hemorrhage cases.

The clinics segment is projected to grow at the fastest CAGR of 8.1% during the forecast period, supported by rising aesthetic and gynecological consultations at outpatient facilities.

• By Distribution Channel

On the basis of distribution channel, the tranexamic acid market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment captured the largest revenue share of 48.5% in 2024, as hospitals remain the primary setting for emergency and surgical drug administration.

The online pharmacy segment is forecasted to grow at the fastest CAGR of 10.3% from 2025 to 2032, driven by rising digital health adoption, ease of access, and growing patient awareness of at-home medication ordering.

Tranexamic Acid Market Regional Analysis

• North America dominated the tranexamic acid market with the largest revenue share of 38.7% in 2024, driven by high surgical volumes, robust healthcare infrastructure, and increasing use of tranexamic acid in trauma, cardiac, orthopedic, and cosmetic surgeries
• The region’s proactive healthcare policies and widespread insurance coverage also facilitate the accessibility of tranexamic acid treatments
• The U.S. accounts for a substantial portion of this share due to its early adoption of antifibrinolytics in clinical settings, rising incidence of bleeding disorders, and expanding cosmetic applications of tranexamic acid in dermatology

U.S. Tranexamic Acid Market Insight

The U.S. tranexamic acid market captured the largest revenue share of 85% within North America in 2024, driven by strong demand across hospitals and surgical centers for perioperative bleeding control. The growing prevalence of trauma injuries and a steady rise in aesthetic treatments such as skin depigmentation therapy are further accelerating market growth. Additionally, the drug’s incorporation into obstetric hemorrhage management protocols continues to support adoption across diverse healthcare settings.

Europe Tranexamic Acid Market Insight

The Europe tranexamic acid market is projected to grow at a significant CAGR of 6.2% from 2025 to 2032, driven by rising usage in dental, gynecological, and orthopedic procedures. Strong support from regulatory bodies such as the EMA for approved indications of tranexamic acid and increasing awareness of blood management strategies contribute to widespread adoption. Countries like Germany, France, and the U.K. are key contributors to regional revenue.

U.K. Tranexamic Acid Market Insight

The U.K. tranexamic acid market is anticipated to register a healthy CAGR of 6.5% during the forecast period, supported by growing clinical use in dental surgeries and skin treatments. The National Health Service (NHS) actively promotes cost-effective antifibrinolytics like tranexamic acid to reduce blood transfusions, particularly in elective surgeries.

Germany Tranexamic Acid Market Insight

The Germany tranexamic acid market is forecasted to expand at a CAGR of 6.3% from 2025 to 2032, driven by a high surgical patient load, a well-established hospital network, and increasing adoption in dermatology clinics. Emphasis on reducing healthcare costs and post-operative complications through antifibrinolytics further supports market expansion.

Asia-Pacific Tranexamic Acid Market Insight

The Asia-Pacific tranexamic acid market is poised to grow at the fastest CAGR of 7.8% from 2025 to 2032, fueled by expanding healthcare access, rising cosmetic procedure rates, and government efforts to curb maternal mortality through better hemorrhage management. The region also benefits from local pharmaceutical manufacturing and increasing OTC availability in topical formats.

Japan Tranexamic Acid Market Insight

The Japan tranexamic acid market is gaining momentum, supported by the widespread use of oral and topical tranexamic acid in aesthetic dermatology. High consumer awareness, aging demographics, and the country’s leading role in cosmetic innovation drive the demand for safe hyperpigmentation treatments.

China Tranexamic Acid Market Insight

The China tranexamic acid market accounted for the largest market revenue share in Asia Pacific in 2024 at 31.2%, driven by robust domestic production, rising elective surgery volumes, and growing demand in both clinical and skincare segments. Favorable government pricing regulations and public health programs also play a critical role in making tranexamic acid widely accessible.

Tranexamic Acid Market Share

The Tranexamic Acid industry is primarily led by well-established companies, including:

• Venkatasai Life Sciences (India)
• Shanghai Shengxin Pharmaceutical & Chemical Co., Ltd. (China)
• VBShilpa (India)
• Hunan Dongting Pharmaceutical Co., Ltd. (China)
• Hainan Huluwa Pharmaceutical Co., Ltd. (China)
• GSK Inc. (U.K.)
• Aurobindo Pharma (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Lupin (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Viatris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Hikma Pharmaceuticals PLC (U.K.)
• Baxter (U.S.)
• Sandoz Group AG (Switzerland)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Amgen Inc. (U.S.)
• Zydus Cadila (India)

Latest Developments in Global Tranexamic Acid Market

• In May 2024, Maxwellia, a champion of women’s health, announced the availability of Evana Heavy Period Relief 500mg tablets (containing tranexamic acid) and Ultravana Period Pain Relief 250mg gastro-resistant tablets (containing naproxen) to assist women in managing heavy and painful periods. Evana is an anti-fibrinolytic indicated for reducing heavy menstrual bleeding (HMB), with the potential to decrease flow by up to 60%. It is the only pharmacy brand available specifically for the relief of heavy menstrual bleeding
• In January 2024, Avenacy, a specialty pharmaceutical company focused on providing essential injectable medications, announced the launch of Tranexamic Acid Injection, USP in the United States as a therapeutic generic equivalent to Cyklokapron, as approved by the U.S. Food and Drug Administration. This injection is indicated for short-term use (2 to 8 days) in patients with hemophilia to reduce or prevent bleeding and minimize the need for replacement therapy during and after tooth extraction
• In September 2022, Shilpa Medicare Limited announced the successful innovation of the world’s first topical hemostatic spray containing Tranexamic Acid, which has received approval from the Central Drugs Standard Control Organization (CDSCO). This groundbreaking spray formulation is user-friendly, portable, easy to apply, and serves as a lifesaving tool. It has been clinically validated in humans and through a robust swine trauma model

SKU-63748